Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mental ability
development and interrupts neurocognitive function. This neuropathological condition is …

Central nervous system (CNS) disorders affect as many as 1.5 billion people globally. The
limited delivery of most imaging and therapeutic agents into the brain is a major challenge …

Cell-penetrating peptides (CPPs) are short peptides (fewer than 30 amino acids) that have
been predominantly used in basic and preclinical research during the last 30 years. Since …

Hydrophilic drugs are proficient therapeutic agents however, delivery of these drugs is a
difficult task. Hence, developing an efficient drug delivery system may require a …

The ability of chitosan (CTS) to promote mucoadhesion, trigger positive/negative surface
interactions, and open tight junctions has inspired researchers to coat lipid-based and …

Small interfering RNA (siRNA) has been expected to be a unique pharmaceutic for the
treatment of broad-spectrum intractable diseases. However, its unfavorable properties such …

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

Central nervous system (CNS) disorders (eg, multiple sclerosis, Alzheimer's disease, etc.)
represent a growing public health issue, primarily due to the increased life expectancy and …

The blood–brain barrier (BBB) plays a fundamental role in protecting the brain from toxic
substances and therefore also controls and restricts the entry of therapeutic agents. The …